MGC Pharmaceuticals's market cap is currently ―. The company's EPS TTM is p-1.95; its P/E ratio is -0.12; MGC Pharmaceuticals is scheduled to report earnings on August 28, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	AU$ 1.89M	AU$ 5.43M	AU$ 1.87M	AU$ 2.35M	AU$ 9.86M
Total Assets	AU$ 18.56M	AU$ 24.24M	AU$ 7.93M	AU$ 13.00M	AU$ 19.99M
Total Debt	AU$ 4.35M	AU$ 6.02M	AU$ 1.90M	AU$ 0.00	AU$ 21.56K
Net Debt	AU$ 2.47M	AU$ 584.33K	AU$ 25.85K	AU$ -2.35M	AU$ -9.84M
Total Liabilities	AU$ 13.38M	AU$ 10.41M	AU$ 4.83M	AU$ 2.20M	AU$ 7.30M
Stockholders Equity	AU$ 5.84M	AU$ 13.83M	AU$ 3.11M	AU$ 10.96M	AU$ 13.93M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in AUD

MGC Pharmaceuticals Earnings and Revenue History

Income Statement >

MGC Pharmaceuticals Debt to Assets

Balance Sheet >

MGC Pharmaceuticals Cash Flow

Cash Flow >

MGC Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing